ANTIBODIES

Contributor Information
- Name Ayham Alnabulsi
- Institute Vertebrate Antibodies Limited
Tool Details
- Tool name: Anti-TMEM2L [V98P4E1*B7]
- Alternate names: CEMIP, KIAA1199, CCSP1, IR2155535, Protein KIAA1199, TMEM2L
- Clone: V98P4E1*B7
- Tool type: Antibodies
- Tool sub-type: Primary antibody
- Class: Monoclonal
- Conjugate: Unconjugated
- Reactivity: Human
- Host: Mouse
- Molecular weight of the target: 153 kDa (isoform 1), 110 kDa (isoform 2)
- Application: ELISA ; IHC
- Strain: Balb/c
- Description: TMEM2L mediates depolymerization of hyaluronic acid (HA) via the cell membrane-associated clathrin-coated pit endocytic pathway. Binds to hyaluronic acid. Hydrolyzes high molecular weight hyaluronic acid to produce an intermediate-sized product, a process that may occur through rapid vesicle endocytosis and recycling without intracytoplasmic accumulation or digestion in lysosomes. Involved in hyaluronan catabolism in the dermis of the skin and arthritic synovium. Positively regulates epithelial-mesenchymal transition (EMT), and hence tumor cell growth, invasion and cancer dissemination. In collaboration with HSPA5/BIP, promotes cancer cell migration in a calcium and PKC-dependent manner. TMEM2L belongs to the TMEM2 family and contains 4 PbH1 repeats. It is expressed in the inner ear. It is expressed in cochlea and vestibule tissues and it may be involved in hearing. Defects in KIAA1199 may be a cause of non-syndromic hearing loss. It is also thought that KIAA1199 is a tumor suppressor that may be involved in establishing cellular mortality in normal human cells.
- Immunogen: Peptide Sequence VTLDTEDHKA peptide immunogen is identical in horse (Equus caballus), 90% identical in mouse (Mus musculus) and rat (Rattus norvegicus)
- Isotype: IgG1 kappa
- Research area: Extracellular Matrix; Cell biology
- Myeloma used: P3X63Ag8.653
- For Research Use Only
Target Details
- Target: Cell migration-inducing and hyaluronan-binding protein
- Target molecular weight: 153 kDa (isoform 1), 110 kDa (isoform 2)
- Target background: TMEM2L mediates depolymerization of hyaluronic acid (HA) via the cell membrane-associated clathrin-coated pit endocytic pathway. Binds to hyaluronic acid. Hydrolyzes high molecular weight hyaluronic acid to produce an intermediate-sized product, a process that may occur through rapid vesicle endocytosis and recycling without intracytoplasmic accumulation or digestion in lysosomes. Involved in hyaluronan catabolism in the dermis of the skin and arthritic synovium. Positively regulates epithelial-mesenchymal transition (EMT), and hence tumor cell growth, invasion and cancer dissemination. In collaboration with HSPA5/BIP, promotes cancer cell migration in a calcium and PKC-dependent manner. TMEM2L belongs to the TMEM2 family and contains 4 PbH1 repeats. It is expressed in the inner ear. It is expressed in cochlea and vestibule tissues and it may be involved in hearing. Defects in KIAA1199 may be a cause of non-syndromic hearing loss. It is also thought that KIAA1199 is a tumor suppressor that may be involved in establishing cellular mortality in normal human cells.
Application Details
- Application: ELISA ; IHC
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15ðC to -25ðC
- Shipping conditions: Shipping at 4ðC